Important progress for Diamyd Medical during the third quarter

Diamyd Medical’s President and CEO comments in the company’s interim report today on several significant advances during the period, including the positive development of the company’s Phase III program.

“I’m very pleased with how the operations has developed this quarter,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “Patient recruitment for the European Phase III study is very successful. Now when we have also received approval to include children from age 10 in the US, we can further accelerate the recruitment," Lindner continues. Diamyd Medical announced during the third quarter that more than half of the patients had been included in the European Phase III study. After the end of the period, the FDA has approved the inclusion of children from age 10 in the US study. The company can now contract more pediatric clinics and further accelerate patient recruitment. During the period, Diamyd Medical also reported that the Swedish Medical Products Agency approved a Phase II study of the Diamyd® vaccine with the objective to prevent or delay the development of type 1 diabetes in children at high risk of developing the disease.

Tags: